NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vivid Dx

Vivid Dx

Private
OxfordHealthcare & Life Scienceshttps://www.vivid-dx.com/

Last Round

Seed

Jul 28, 2026

Total Funding Raised

$20.56M

Company Overview

Vivid Dx is a health tech company that develops a precision diagnostic platform for the rapid detection of sepsis-causing pathogens and antimicrobial resistance using Raman spectroscopy and AI-driven analysis.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware + Subscription, Government Contracts, Services & Consulting

AI Layer

Application

Keywords

rapid diagnostic platformsepsis detectionantimicrobial resistanceAMRantimicrobial susceptibility testingASTRaman spectroscopysingle-cell analysisculture-free diagnosticsAI diagnosticspathogen identificationpoint of care testingPOCTmedical deviceclinical laboratory

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivid Dx Comparables

Compare Vivid Dx with similar companies based on industry and business-model similarity.

Vivid Dx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Astek Diagnostics
87%
iFAST Diagnostics
86%
Nostics
85%

Vivid Dx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJul 28, 2026
GrantApr 1, 2025
Early FundingApr 1, 2024
GrantDec 1, 2023
GrantMay 1, 2023

Vivid Dx Investors

Notable investors and investment history

Vivid Dx investors
InvestorRounds
Oxford Science EnterprisesSeed, Early Funding
JIMCOSeed
Innovate UKGrant
Cedars-Sinai Intellectual Property CompanySeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 14, 2026

    Grew 23% QoQ, from 13 to 16 employees.

  • Oct 14, 2025

    Grew 44% QoQ from 9 to 13 employees.

Vivid Dx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vivid Dx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vivid Dx's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range16
Year Founded2022
Last FundingJul 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.